[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I. and Jemal, A. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Kole, C., Charalampakis, N., Tsakatikas, S., Kouris, N., Papaxoinis, G. and Michalis, V.K. (2022) Immunotherapy for Gastric Cancer: A 2021 Update. Immunother-apy, 14, 41-64. https://doi.org/10.2217/imt-2021-0103
|
[3]
|
Kawazoe, A., Shitara, K., Boku, N., Yoshikawa, T. and Terashima, M. (2021) Current Status of Immunotherapy for Advanced Gastric Cancer. Japanese Journal of Clinical Oncology, 51, 20-27. https://doi.org/10.1093/jjco/hyaa202
|
[4]
|
Zhang, Y., Yang, Y., Chen, Y.R., Lin, W., Chen, X.L. and Liu, J. (2022) PD-L1: Biological Mechanism, Function, and Immunotherapy in Gastric Cancer. Frontiers in Immunology, 13, Article ID: 1060497.
https://doi.org/10.3389/fimmu.2022.1060497
|
[5]
|
Eliza, H., Alicia, F.C.O., Demetris, P., Rao, S., Ashley, S. and Charalambous, H. (2011) Docetaxel and Irinotecan as Second-Line Therapy for Advanced Oesophagogastriccancer. Eu-ropean Journal of Cancer (Oxford, England : 1990), 47, 1146-1151. https://doi.org/10.1016/j.ejca.2010.12.021
|
[6]
|
Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M. and Tsumura, T. (2013) Randomized, Open-Label, Phase III Study Comparing Irinotecan with Paclitaxel in Patients with Advanced Gastric Cancer without Severe Peritoneal Metastasis after Failure of Prior Combination Chemotherapy Using Fluoropyrimidine plus Platinum: WJOG 4007 Trial. Journal of Clinical Oncology: Official Journal of the American Soci-ety of Clinical Oncology, 31, 4438-4444.
https://doi.org/10.1200/JCO.2012.48.5805
|
[7]
|
Zhao, Q., Lian, C.H., Huo, Z.B., Li, M., Liu, Y. and Fan, L.Q. (2020) The Efficacy and Safety of Neoadjuvant Chemotherapy on Patients with Advanced Gastric Cancer: A Multicenter Randomized Clinical Trial. Cancer Medicine, 9, 5731-5745. https://doi.org/10.1002/cam4.3224
|
[8]
|
Tian, Y., Zhao, Q., Li, Y., Fan, L.Q., Zhang, Z.D. and Zhao, X.F. (2021) Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. Gastroenterology Re-search and Practice, 2021, Article ID: 5590626. https://doi.org/10.1155/2021/5590626
|
[9]
|
Yu, Y.Y., Fang, Y., Shen, Z.B., Wang, Y., Yan, M. and Cao, H. (2019) Oxaliplatin plus Capecitabine in the Perioperative Treatment of Lo-cally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study. The Oncologist, 24, 1311-e989. https://doi.org/10.1634/theoncologist.2019-0416
|
[10]
|
Xue, K., Ying, X.J., Bu, Z.D., Wu, A., Li, Z.W. and Tang, L. (2018) Oxaliplatin plus S-1 or Capecitabine as Neoadjuvant or Adjuvant Chemotherapy for Locally Advanced Gastric Cancer with D2 Lymphadenectomy: 5-Year Follow-Up Results of a Phase II-III Randomized Trial. Chinese Journal of Cancer Research, 30, 516-525.
https://doi.org/10.21147/j.issn.1000-9604.2018.05.05
|
[11]
|
Leowattana, W., Leowattana, P. and Leowattana, T. (2023) Immunotherapy for Advanced Gastric Cancer. World Journal of Methodology, 13, 79-97. https://doi.org/10.5662/wjm.v13.i3.79
|
[12]
|
Wang, J.Z., He, Y.D., Zhang, B.W., Lv, H.F., Nie, C.Y. and Chen, B.B. (2022) The Efficacy and Safety of Sintilimab Combined with Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer. Frontiers in Oncology, 12, Article ID: 924149. https://doi.org/10.3389/fonc.2022.924149
|
[13]
|
Jin, X., Liu, Z.R., Yang, D.X., Yin, K. and Chang, X.S. (2022) Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. Frontiers in Immunology, 13, Article ID: 948647.
https://doi.org/10.3389/fimmu.2022.948647
|
[14]
|
Zhang, L., Mai, W.Q., Jiang, W.Y. and Geng, Q. (2020) Sintili-mab: A Promising Anti-Tumor PD-1 Antibody. Frontiers in Oncology, 10, Article ID: 594558. https://doi.org/10.3389/fonc.2020.594558
|
[15]
|
Sun, L.T., Zhang, L.Y., Yu, J.R., Zhang, Y., Pang, X. and Ma, C.H. (2020) Clinical Efficacy and Safety of Anti-PD-1/ PD-L1 Inhibitors for the Treatment of Advanced or Metastatic Cancer: A Systematic Review and Meta-Analysis. Scientific Reports, 10, Article No. 2083. https://doi.org/10.1038/s41598-020-58674-4
|
[16]
|
Muro, K., Chung, H.C., Shankaran, V., Geva, R., Catenacci, D. and Gupta, S. (2016) Pembrolizumab for Patients with PD-L1-Positive Advanced Gastric Cancer (KEYNOTE-012): A Multicentre, Open-Label, Phase 1b Trial. The Lancet Oncology, 17, 717-726. https://doi.org/10.1016/S1470-2045(16)00175-3
|
[17]
|
Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y. and Kato, K. (2017) Nivolumab in Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet (London, England), 390, 2461-2471. https://doi.org/10.1016/S0140-6736(17)31827-5
|
[18]
|
Zhang, Z., Liu, N. and Sun, M. (2023) Research Progress of Immunotherapy for Gastric Cancer. Technology in Cancer Research & Treatment, 22. https://doi.org/10.1177/15330338221150555
|
[19]
|
Fuchs, C.S., Doi, T., Jang, R.W., Muro, K., Satoh, T. and Ma-chado, M. (2018) Safety and Efficacy of Pembrolizumab Monotherapy in Patients with Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncology, 4, e180013. https://doi.org/10.1001/jamaoncol.2018.0013
|
[20]
|
Kexin, L., Zhang, A., Li, X., Zhang, H.T. and Zhao, L.M. (2021) Advances in Clinical Immunotherapy for Gastric Cancer. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1876, Article ID: 188615.
https://doi.org/10.1016/j.bbcan.2021.188615
|
[21]
|
Bang, Y.-J., Ruiz, E.Y., Cutsem, E.V., Lee, K.-W., Wyrwicz, L. and Schenker, M. (2018) Phase III, Randomised Trial of Avelumab versus Physician’s Choice of Chemotherapy as Third-Line Treatment of Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer: Primary Analysis of JAVELIN Gastric 300. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 29, 2052-2060. https://doi.org/10.1093/annonc/mdy264
|
[22]
|
Kon, E. and Benhar, I. (2019) Immune Checkpoint Inhib-itor Combinations: Current Efforts and Important Aspects for Success. Drug Resistance Updates, 45, 13-29.
|
[23]
|
Davern, M. and Lysaght, J. (2020) Cooperation between Chemotherapy and Immunotherapy in Gas-troesophageal Cancers. Cancer Letters, 495, 89-99. https://doi.org/10.1016/j.canlet.2020.09.014
|
[24]
|
Burtness, B., Harrington, K.J., Greil, R., Soulières, D., Tahara, M. and Castro Jr., G.D. (2019) Pembrolizumab Alone or with Chemo-therapy versus Cetuximab with Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study. The Lancet (London, England), 394, 1915-1928. https://doi.org/10.1016/S0140-6736(19)32591-7
|
[25]
|
Hodge, J.W., Garnett, C.T., Farsaci, B., Palena, C., Tsang, K.-Y. and Ferrone, S. (2013) Chemotherapy-Induced Immunogenic Modulation of Tumor Cells Enhances Killing by Cytotoxic T Lymphocytes and Is Distinct from Immunogenic Cell Death. International Journal of Cancer, 133, 624-636. https://doi.org/10.1002/ijc.28070
|
[26]
|
Li, J.-Y., Chen, Y.-P., Li, Y.-Q., Liu, N. and Ma, J. (2021) Chemotherapeu-tic and Targeted Agents Can Modulate the Tumor Microenvironment and Increase the Efficacy of Immune Checkpoint Blockades. Molecular Cancer, 20, Article No. 27. https://doi.org/10.1186/s12943-021-01317-7
|
[27]
|
Seliger, B. (2019) Combinatorial Approaches with Checkpoint Inhibitors to Enhance Anti-Tumor Immunity. Frontiers in Immunol-ogy, 10, Article No. 999. https://doi.org/10.3389/fimmu.2019.00999
|
[28]
|
Leong, A. and Kim, M. (2020) The An-giopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Pa-tients with Advanced Cancer. International Journal of Molecular Sciences, 21, Article No. 8689. https://doi.org/10.3390/ijms21228689
|
[29]
|
Zhou, S. and Zhang, H. (2020) Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications. Anti-Cancer Agents in Medicinal Chem-istry, 20, 768-776.
https://doi.org/10.2174/1871520620666200207091653
|
[30]
|
Zhu, N., Weng, S., Wang, J., Chen, J.Q., Yu, L.Z. and Fang, X.F. (2019) Preclinical Rationale and Clinical Efficacy of Antiangiogenic Therapy and Immune Checkpoint Blockade Combination Therapy in Urogenital Tumors. Journal of Cancer Research and Clinical Oncology, 145, 3021-3036. https://doi.org/10.1007/s00432-019-03044-5
|
[31]
|
Bang, Y.-J., Kang, Y.-K., Catenacci, D.V., Muro, K., Fuchs, C.S. and Geva, R. (2019) Pembrolizumab Alone or in Combination with Chemotherapy as First-Line Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Results from the Phase II Nonrandom-ized KEYNOTE-059 Study. Gastric Cancer, 22, 828-837.
https://doi.org/10.1007/s10120-018-00909-5
|
[32]
|
Shitara, K., Cutsem, E.V., Bang, Y.-J., Fuchs, C., Wyrwicz, L. and Lee, K.-W. (2020) Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncology, 6, 1571-1580.
https://doi.org/10.1001/jamaoncol.2020.3370
|
[33]
|
Boku, N., Ryu, M.-H., Kato, K., Chung, H.C., Minashi, K. and Lee, K.-W. (2019) Safety and Efficacy of Nivolumab in Combination with S-1/Capecitabine plus Oxaliplatin in Patients with Previously Untreated, Unresectable, Advanced, or Recurrent Gastric/Gastroesophageal Junction Cancer: Interim Results of a Randomized, Phase II Trial (ATTRACTION- 4). Annals of Oncology, 30, 250-258. https://doi.org/10.1093/annonc/mdy540
|
[34]
|
Kang, Y.-K., Chen, L.-T., Ryu, M.-H., Oh, D.-Y., Oh, S.C. and Chung, H.C. (2022) Nivolumab plus Chemotherapy versus Placebo plus Chemotherapy in Patients with HER2-Negative, Untreated, Unresectableadvanced or Recurrent Gastric or Gastro-Oesophageal Junction Cancer (ATTRACTION-4): A Randomised, Multicentre, Double-Blind, Placebo- Controlled, Phase 3 Trial. The Lancet Oncology, 23, 234-247. https://doi.org/10.1016/S1470-2045(21)00692-6
|
[35]
|
Janjigian, Y.Y., Shitara, K., Moehler, M., Garrido, M., Sal-man, P. and Shen, L. (2021) First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gas-tric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. The Lancet (London, England), 398, 27-40.
https://doi.org/10.1016/S0140-6736(21)00797-2
|
[36]
|
Chung, H.C., Bang, Y.-J., Fuchs, C.S., Qin, S.-K., Satoh, T. and Shitara, K. (2021) First-Line Pembrolizumab/Placebo plus Trastuzumab and Chemotherapy in HER2-Positive Ad-vanced Gastric Cancer: KEYNOTE-811. Future Oncology (London, England), 17, 491-501. https://doi.org/10.2217/fon-2020-0737
|
[37]
|
Xu, J., Jiang, H., Pan, Y., Gu, K., Cang, S. and Han, L. (2021) LBA53 Sintilimab plus Chemotherapy (Chemo) versus Chemo as First-Line Treatment for Advanced Gastric or Gastroesophage-al Junction (G/GEJ) Adenocarcinoma (ORIENT- 16): First Results of a Randomized, Double-Blind, Phase III Study. Annals of Oncology, 32, S1331.
https://doi.org/10.1016/j.annonc.2021.08.2133
|
[38]
|
Grierson, P., Lim, K.-H. and Amin, M. (2017) Immunotherapy in Gastrointestinal Cancers. Journal of Gastrointestinal Oncology, 8, 474-484. https://doi.org/10.21037/jgo.2017.05.01
|
[39]
|
Karlsson, M., Marits, P., Dahl, K., Dagöö, T., Enerbäck, S. and Thörn, M. (2010) Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer. Annals of Surgical Oncology, 17, 1747-1757.
https://doi.org/10.1245/s10434-010-0920-8
|